Omnicell posts Q4 2025 revenue of $314M and non-GAAP EPS of $0.40 and FY 2025 revenue of $1.185B and EPS of $1.62, issues Q1 and full-year 2025 guidance, and launches its Titan XT medication dispensing system with a projected >$2.5B eight-year refresh-cycle. The company also details its 2026 outlook, citing a $15M tariff headwind and $10M in ERP transition costs baked into full-year guidance.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.